Prosecution Insights
Last updated: November 16, 2026
Application No. 19/044,319

SYSTEM AND METHOD FOR CLEARING AN OBSTRUCTION FROM THE PATH OF A SURGICAL LASER

Non-Final OA §102§103
Filed
Feb 03, 2025
Priority
Jul 16, 2018 — divisional of 10/821,023 +5 more
Examiner
JIAN, SHIRLEY XUEYING
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Vialase Inc.
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
86%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
485 granted / 764 resolved
-6.5% vs TC avg
Strong +22% interview lift
Without
With
+22.5%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
26 currently pending
Career history
805
Total Applications
across all art units

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The current application has an effective filing date of 07/16/2018 according to the priority chain on the record. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1-2, 4-6 and 10-16 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Raksi et al. US 2011/0028951 A1 (hereinafter “Raksi”). Regarding claim 1, Raksi discloses a method of treating a target volume of ocular tissue (Abstract: eye-surgical laser system and method, see Figs. 9-10: laser delivery system 1’) , the method comprising: moving a focus of a laser through the target volume of ocular tissue, the moving comprising transverse scanning (XY transverse scanning) the focus between at least one of a first circumferential boundary and a second circumferential boundary of the target volume of ocular tissue, and a first azimuthal boundary and a second azimuthal boundary of the target volume of ocular tissue, while simultaneously axial scanning (Z depth scanning) the focus between a distal extent and a proximal extent of the target volume of ocular tissue (see Figs. 9-10 and [0023] “ wherein the position of the focal spot can be moved simultaneously in the Z and the XY direction to sweep a curved target line” XY scanner moves in the transverse direction, while Z scanner moves in the distal direction simultaneously to scan a focal spot of the laser system in a target ocular tissue); and photodisrupting the target volume of ocular tissue at a plurality of spots as the focus is moved through the target volume of ocular tissue. ([0075] laser-induced photodisruption) Regarding claim 2, Rakdi discloses the method of claim 1, further comprising repeating the moving and photodisrupting a plurality times. ([0075] “… pulses can be delivered to a sequence of spots which are contiguous, nearly contiguous, or are separated by controlled distances” implies a photodisrupting a plurality of time as recited in this claim) Regarding claim 4, Raksi discloses the method of claim 1, wherein the transverse scanning further comprises scanning the focus between both of the first circumferential boundary and the second circumferential boundary, and the first azimuthal boundary and the second azimuthal boundary. ([0023] scanning in a curve target line encompasses “focus between both of the first circumferential boundary and the second circumferential boundary, and the first azimuthal boundary and the second azimuthal boundary” as recited in this claim) Regarding claim 5, Raksi discloses the method of claim 4, wherein: a major dimension of a major scan line between one of the first circumferential boundary and the second circumferential boundary, and the first azimuthal boundary and the second azimuthal boundary is greater than a minor dimension of a minor scan line between the other of the first circumferential boundary and the second circumferential boundary, and the first azimuthal boundary and the second azimuthal boundary, and the focus is scanned along the major scan line to an end of the major scan line before being moved along the minor scan line. ([0142] curve target line encompasses the recited boundaries in this claim) Regarding claim 6, Raksi discloses the method of claim 1, wherein the axial scanning (Z-depth) comprises: moving the focus at an exiting velocity while moving the focus in the direction of the proximal extent, and moving the focus at an entering velocity while moving the focus in the direction of the distal extent. ([0023-0024] Z scanning speed) Regarding claim 10, Raksi discloses the method of claim 1, wherein the target volume of ocular tissue is entirely within ocular tissue. (see [0048-0049] corneal and lens procedures imply target volume of ocular tissue; [0058] “…configured to deliver the femtoscond laser pulses into the entire surgical volume of lens of the eye”) Regarding claim 11, Raksi discloses the method of claim 1, wherein at least a portion of the target volume of ocular tissue encompasses adjacent anatomy. ([0051-0052] cornea and the anterior aqueous chamber; [0170-0175] anterior segment surgical procedure, Z scanner reaches a focal depth up to 10mm) Regarding claim 12, Raksi discloses the method of claim 11, wherein the adjacent anatomy comprises one of an anterior chamber and an interior of a Schlemm's canal. ([0051-0052] cornea and the anterior aqueous chamber) Regarding claim 13, Raksi discloses the method of claim 1, wherein photodisrupting tissue comprises applying optical energy to the tissue while the focus is at the plurality of spots. ([0075] Such lasers use relatively low energy per pulse to localize the tissue effect caused by the laser-induced photodisruption.) Regarding claim 14, Raksi discloses the method of claim 1, further comprising: detecting the distal extent of the target volume of ocular tissue; and detecting the proximal extent of the target volume of ocular tissue. ([0064] “The imaging system is configured to image portions of a surgical region to establish three dimensional positional references based on the internal features of the eye”) Regarding claim 15, Raksi discloses the method of claim 14, wherein the distal extent of the target volume of ocular tissue and the proximal extent of the target volume of ocular tissue are detected based on one or more images of ocular tissue. ([0013-0014] at least five reference points in a target region; also see [0055]) Regarding claim 16, Raksi discloses the method of claim 15, wherein the one or more images of ocular tissue are obtained using one or more of optical imaging techniques, multiphoton imaging techniques, and opto-mechanical imaging techniques. ([0055] optical imaging; [0062, 0064-0065] Optical Coherence Tomography (OCT) system) Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 3 is rejected under 35 U.S.C. 103 as being unpatentable over Raksi as applied to claim 1 above, and in view of de Juan, JR et al. US 2014/0069438 A1 (hereinafter “Juan”). Regarding claim 3, Raksi discloses the method of claim 2, but does not disclose further comprising determining a number corresponding to the plurality of times based on prior moving and photodisrupting related to ex vivo tissue, or in vivo tissue across a patient population previously subjected to a similar laser treatment. Juan, another prior art reference in analogous art, discloses a method for treating a patient via ophthalmic (RPK) surgery and providing an optical covering, wherein the results of the surgery with said optical covering are compared to similar patient population are compared ([0504] and claim 276, 0278). Similarly, it would have obvious to a person of ordinary skill in the art at the time of invention to modify Raksi in view of Juan, to consider performance of a similar patient population during surgical planning, the motivation is to set baselines and calibrate the system so as to optimize surgery. Claim Objection/Allowable Subject Matter Claims 7-9 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Raksi US 2018/0028355 A1: [0077] “Laser beam 200 next enters z-scanner 208, which is configured to scan laser beam 200 to a particular z-depth along optical axis 114. Transversal scanner 206 and z-scanner 208 together provide scanning in three dimensions and may comprise any suitable configuration of lenses and/or mirrors.” Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHIRLEY X JIAN whose telephone number is (571)270-7374. The examiner can normally be reached M-F 8:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Benjamin Klein can be reached at 571-270-5213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHIRLEY X JIAN/Primary Examiner, Art Unit 3792 September 24, 2026
Read full office action

Prosecution Timeline

Feb 03, 2025
Application Filed
Sep 29, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788993
ACTIVITY DETECTION FOR CARDIAC REMODELING PACING
3y 9m to grant Granted Nov 10, 2026
Patent 12778453
MONITORING DEVICE, ASSEMBLY OF SAID MONITORING DEVICE WITH A SUPPORT, AND MONITORING SYSTEM
2y 10m to grant Granted Nov 03, 2026
Patent 12773193
ORTHOPEDIC INSTRUMENT CONNECTION MECHANISMS AND RELATED ASSEMBLIES AND SYSTEMS
2y 7m to grant Granted Oct 27, 2026
Patent 12758341
CABLE DRIVE LIMITED SLIP CAPSTAN AND SHAFT
2y 5m to grant Granted Oct 13, 2026
Patent 12746154
NON-INVASIVE AND MINIMALLY INVASIVE LASER SURGERY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN THE EYE
2y 0m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
86%
With Interview (+22.5%)
Low
PTA Risk
Based on 764 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month